Stock 455 TIANDA PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials Tianda Pharmaceuticals Limited

Equities

455

KYG887471038

Pharmaceuticals

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:05 2024-05-31 am EDT 		5-day change 1st Jan Change
0.23 HKD -8.00% Intraday chart for Tianda Pharmaceuticals Limited -4.96% +5.50%
May. 16 Tianda Pharmaceuticals Unit Gets Registration Go-Ahead for Acute Coronary Drug from Chinese Regulator MT
Mar. 26 Tianda Pharmaceuticals Limited Proposes Final Dividend for the Year Ended 31 December 2023, Payable on 28 June 2024 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 468.7 369.8 296.7 688 870.8 468.7
Enterprise Value (EV) 1 -28.93 -78.38 8.636 595.6 646.6 411.4
P/E ratio 46.9 x 139 x 94.5 x -25.4 x -15.9 x -19.4 x
Yield 1.61% 0.64% 0.94% 0.81% 0.86% 1.19%
Capitalization / Revenue 1.3 x 0.7 x 0.6 x 1.45 x 1.59 x 0.88 x
EV / Revenue -0.08 x -0.15 x 0.02 x 1.26 x 1.18 x 0.77 x
EV / EBITDA -0.78 x -3.09 x 0.38 x -28.6 x -23.2 x -432 x
EV / FCF -0.5 x 0.67 x -0.07 x -3.23 x 6.34 x -3.66 x
FCF Yield -201% 150% -1,430% -31% 15.8% -27.3%
Price to Book 0.55 x 0.48 x 0.41 x 0.91 x 1.39 x 0.79 x
Nbr of stocks (in thousands) 2,150,042 2,150,042 2,150,042 2,150,042 2,150,042 2,150,042
Reference price 2 0.2180 0.1720 0.1380 0.3200 0.4050 0.2180
Announcement Date 7/26/18 7/25/19 7/28/20 7/23/21 4/28/23 4/25/24
1HKD in Million2HKD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 361.6 527 491.5 474.3 546.7 532.1
EBITDA 1 37.02 25.4 22.94 -20.84 -27.88 -0.953
EBIT 1 14.97 9.232 9.471 -34.36 -70.14 -29.02
Operating Margin 4.14% 1.75% 1.93% -7.24% -12.83% -5.45%
Earnings before Tax (EBT) 1 29.94 26.17 15.93 -27.44 -63.85 -25.69
Net income 1 10.01 2.657 3.143 -27.14 -54.64 -24.16
Net margin 2.77% 0.5% 0.64% -5.72% -9.99% -4.54%
EPS 2 0.004653 0.001235 0.001461 -0.0126 -0.0254 -0.0112
Free Cash Flow 1 58.28 -117.6 -123.5 -184.5 101.9 -112.4
FCF margin 16.12% -22.31% -25.12% -38.9% 18.64% -21.13%
FCF Conversion (EBITDA) 157.46% - - - - -
FCF Conversion (Net income) 582.38% - - - - -
Dividend per Share 2 0.003500 0.001100 0.001300 0.002600 0.003467 0.002600
Announcement Date 7/26/18 7/25/19 7/28/20 7/23/21 4/28/23 4/25/24
1HKD in Million2HKD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - - -
Net Cash position 1 498 448 288 92.4 224 57.3
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 58.3 -118 -123 -184 102 -112
ROE (net income / shareholders' equity) 2.61% 1.88% 1.12% -3.34% -2.74% -4.01%
ROA (Net income/ Total Assets) 0.96% 0.57% 0.61% -2.08% -2.4% -1.81%
Assets 1 1,042 470.2 512.4 1,306 2,277 1,335
Book Value Per Share 2 0.3900 0.3600 0.3400 0.3500 0.2900 0.2800
Cash Flow per Share 2 0.2300 0.1800 0.1400 0.1100 0.1600 0.0800
Capex 1 8.63 33.6 93.9 146 33.3 49.3
Capex / Sales 2.39% 6.38% 19.11% 30.71% 6.09% 9.26%
Announcement Date 7/26/18 7/25/19 7/28/20 7/23/21 4/28/23 4/25/24
1HKD in Million2HKD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
TIANDA PHARMACEUTICALS LIMITED Stock Tianda Pharmaceuticals Limited
+5.50% 63.24M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+40.73% 739B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+32.83% 598B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.30% 353B
MERCK & CO., INC. Stock Merck & Co., Inc.
+15.15% 318B
ABBVIE INC. Stock AbbVie Inc.
+4.05% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.00% 240B
ROCHE HOLDING AG Stock Roche Holding AG
-5.52% 206B
AMGEN INC. Stock Amgen Inc.
+6.17% 164B
PFIZER, INC. Stock Pfizer, Inc.
-0.45% 162B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 455 Stock
  4. Financials Tianda Pharmaceuticals Limited